NEAT ID INTEGRATION GRANT

​

Seven NEAT ID Integration Grants have been awarded to date. NEAT ID has also supported junior doctors travelling to international conferences and provided grants to support panel meetings.

​

​There are currently no NEAT ID grant calls open. Details of future funding opportunities will be posted here when available.

​

What is a NEAT ID Integration Grant? 

​

• A scientific grant given to a minimum of two countries in collaboration, which includes at least one NEAT ID site.

• They are preferentially provided to studies which may relate to ongoing NEAT ID trials

• Cover a wide range of infectious diseases which NEAT ID are interested in, HIV, Hepatitis, MPX, COVID  

• The value of the grant is around 100,000 euros 

• Reviewed by an independent international panel of experts 

​

2022 NEAT ID Integration Grants 

​

Dr Merle Henderson 

Imperial College London

Title: Longitudinal changes in plasma neuronal markers in persons with HIV commencing ART.

Status: Closed. 

​Publications: 

• CROI Conference 2025 (San Francisco, USA) – poster presentation

• HIV CNS Day 2025 (London, U.K.) – oral abstract presentation

• BHIVA Spring Conference 2025 (Brighton, U.K.) – oral abstract presentation

• Final manuscript approved in HIV Medicine

 

Dr Linos Vandekerckhove 

Ghent university

Title: Feasibility evaluation of anti-HIV Antibody-secreting Chimeric Antigen Receptor T cells as a potential cure in acute seroconverters

Status: Closed. 

Publications: 

• Oral Presentation – IAS 2025

• Awarded the IAS/ANRS Lange/van Tongeren Prize for Young Investigators, recognizing innovation, originality, and scientific quality in HIV research

• Poster presentation – CROI 2026

• Final manuscript was published in Frontiers: file:///C:/Users/lvdkerck/Downloads/fimmu-17-1822773.pdf

​

Dr Christoph Boesecke

Bonn University Hospital

Title: NEAT-No-C: A multicenter European cohort on annual HCV incidence in MSM in Europe with an embedded European HCV biobank

Status: Closed early due to recruitment. 

​

2018 NEAT ID Integration Grant

Professor Charles Béguelin Grant 2018

Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland

Kinetics of Hepatitis B Virus markers in treated HIV/HBV-coinfected patients

Publications:

1. Published in Liver International (2023). “Hepatitis Delta infection among persons living with HIV in Europe – Published in Liver International 2023” https://pubmed.ncbi.nlm.nih.gov/36625770/

2. Published in Frontiers in Medicine (2022). “Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection” https://www.frontiersin.org/articles/10.3389/fmed.2022.988356/full

3. Published in CID (2022). “Hepatitis B Virus replication during tenofovir therapy is frequent in human immunodeficiency virus/HBV coinfection.” https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac823/6761485?redirectedFrom=fulltext

 

2016 NEAT ID Integration Grant

​

Dr Christoph Boeseck Grant 2016

Bonn University Hospital  NEAT 001 Follow Up 

Re-infection and DAA-based treatment uptake in acute HCV coinfection within the European acute HCV cohort PROBE-C

Publications:

1. Published in Clinical Infectious Diseases. “Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus–Positive Men Who Have Sex With Men (PROBE-C Study)” https://pubmed.ncbi.nlm.nih.gov/36004410/​

Using Partial Data: 

 2. Published In Clinical Infectious Diseases. “Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After        Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era” https://pubmed.ncbi.nlm.nih.gov/31562816/ ​

 3. Published in Clinical Infectious Diseases. “Clinical Infectious Diseases publication containing partial data from Probe-C Cohort” 

​

Has been awarded NEAT ID Integration Grant 2022 for follow up.

​

Dr Jose Arribas Grant 2016

​

Foundation for Biomedical Research of University, Hospital La Paz, Madrid 

Telomere length changes after darunavir-ritonavir combined with either raltegravir or tenofovir- emtricitabine in antiretroviral-naive adults with HIV-1: a sub-study of the NEAT001/ANRS143 

Publications: 

 

1. Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. J Infect Dis. 2018 Oct 5;218(10):1523-1530. IF 5.60

2. Alejos B, Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Schwimmer C, Bernardino JI, Rodes B, Esser S, Goujard C, Sarmento-Castro R, De Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ANRS 143 Study Group. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial. HIV Med. 2019 Nov;20(10):691-698. IF 3.556 

 

Prof. Gilles Wandeler Grant 2016

​

University of Bern

Multi-cohort study to inform hepatocellular carcinoma screening strategies in HIV/HBV-coinfected individuals on tenofovir-containing therapy

Publications: 

1. Published in J Hepatol (2019). “Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies” https://pubmed.ncbi.nlm.nih.gov/30965070/

2. Published in J Hepatol (2023). “External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.  https://pubmed.ncbi.nlm.nih.gov/36690280/

3. Oral abtrsact presented at CROI 2023. “External validation of the PAGE-B score to estimate the risk of hepatocellular carcinoma in persons living with HIV and hepatitis B”

​

Research Grants

​

Prof Esteban Martinez

Hospital Clinic & University of Barcelona

NEAT 022 Sub-Studies: An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a  boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression

Publications: 

• Published in J Antimicrob Chemother (2023). “Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.” 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. PMID: 37539492

• Published in CID (2023) “Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.” 5;77(7):991-1009. doi: 10.1093/cid/ciad297. PMID: 37207617

• Published in CID (2023) “Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.” 76(5):861-870. doi: 10.1093/cid/ciac827. PMID: 36259527 Clinical Trial.

• Published in J Antimicrob Chemother (2022). “Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.” 29;77(7):1980-1988. doi: 10.1093/jac/dkac117. PMID: 35411401 Clinical Trial.

• Published in J Antimicrob Chemother (2021). “Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.” 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. PMID: 34120186 Clinical Trial.

• Published in J Antimicrob Chemother (2020). “Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.” 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292.

PMID: 32737482 Clinical Trial.